Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Project REACH: Telehealth at syringe service programs to help people who use drugs access HIV-related care

Official title: Project REACH: A Comprehensive Telehealth Intervention at Syringe Service Programs to Engage People Who Use Drugs

Run by University of Minnesota · NCT07433712 · Data updated 2026-11-12

A telehealth program at syringe service sites will try to connect adults who use drugs with HIV-related services to see if it is feasible and acceptable and may help them get care.

More Substance Use trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment121 (estimated)
SponsorUniversity of Minnesota
Academic / other
Locations1 site (Minneapolis, Minnesota)
StatusRecruiting
StartedMay 6, 2026
Main results expectedMay 1, 2028
Study endsMay 1, 2028
Registry record updatedMay 19, 2026
Trial IDNCT07433712 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18+ who use illicit substances, are English-speaking, have lived in the study area for at least 6 months, and have active health insurance at the start.

Probably not a fit

Individuals unable or unwilling to provide informed consent may not benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project tests a telehealth intervention delivered at syringe service programs to improve access to HIV-related evidence-based interventions for people who use drugs, including those who inject. The study will assess feasibility, acceptability, and preliminary effectiveness in a real-world SSP setting. Participants are adults who use illicit substances and meet local criteria, with English proficiency and active health insurance, recruited at the University of Minnesota. The trial is conducted at a single site in Minneapolis, led by the University of Minnesota. No comparative treatment arm is described, and the phase is not specified as traditional clinical phase nomenclature.

Why it matters

Potential benefit: If successful, the approach could improve access to HIV-related prevention and care services for people who use drugs through existing SSP infrastructure.

How similar studies have gone: Previous work in telehealth and SSP-based interventions shows potential to improve linkage to HIV-related services, though this specific setup is comparatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
People Who Use Drugs Inclusion Criteria:

* 18 years of age or older
* able to speak and understand English
* have used an illicit substance at least once in the past year
* have lived in the study area (in or near their city of their recruitment) for at least 6 months
* have active health insurance by the start of the Project REACH trial date

People Who Use Drugs Exclusion Criteria:

* Unable or unwilling to provide informed consent

Stakeholder Inclusion Criteria:

* 18 years of age or older
* able to speak and understand English
* currently employed or volunteering with the PCC or an SSP enrollment site for at least one year at the time of the interview OR hired as a study navigator at one of the four enrollment sites

Stakeholder Exclusion Criteria:

* Unable or unwilling to provide informed consent

Where it's running

  • University of Minnesota
    Minneapolis, Minnesota, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.